Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Last updated: January 15, 2009
Sponsor: Bernstein, Jonathan A., M.D.
Overall Status: Trial Status Unknown

Phase

4

Condition

Acute Rhinitis

Common Cold

Allergy

Treatment

N/A

Clinical Study ID

NCT00406094
NARES
  • Ages 18-65
  • All Genders

Study Summary

The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 - 65 years

  • Diagnosed with NARES

Exclusion

Exclusion Criteria:

  • Smokers, exposed to passive smoke

  • Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), orvasomotor rhinitis (VMR)

Study Design

Total Participants: 6
Study Start date:
November 01, 2006
Estimated Completion Date:
December 31, 2009

Study Description

Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.

Connect with a study center

  • Bernstein Allergy Group

    Cincinnati, Ohio 45231
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.